Search Results - "Gasink, Christopher"

S219 Evaluation of Aspartate Aminotransferase to Platelet Ratio Index and Fibrosis-4 Index Stabilization in the Phase 3 POISE Trial of Obeticholic Acid for the Treatment of Primary Biliary Cholangitis by Bonder, Alan, Wheeler, Darren, Li, Jing, Gasink, Christopher, Gish, Robert G.

Get full text

S220 Stabilization of Enhanced Liver Fibrosis and Liver Stiffness Measures in the Open-Label Extension of the Phase 3 POISE Trial of Obeticholic Acid for the Treatment of Primary Biliary Cholangitis by Gish, Robert G., Wheeler, Darren, Li, Jing, Gasink, Christopher, Bonder, Alan

Get full text

Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease by Sandborn, William J, Gasink, Christopher, Gao, Long-Long, Blank, Marion A, Johanns, Jewel, Guzzo, Cynthia, Sands, Bruce E, Hanauer, Stephen B, Targan, Stephan, Rutgeerts, Paul, Ghosh, Subrata, de Villiers, Willem J.S, Panaccione, Remo, Greenberg, Gordon, Schreiber, Stefan, Lichtiger, Simon, Feagan, Brian G

“…In this randomized trial involving adults with Crohn's disease in whom anti–tumor necrosis factor therapy had failed, ustekinumab, an antibody against…”
Get full text

S123 Effect of Obeticholic Acid on Reduction and Normalization of Alanine Aminotransferase and Aspartate Aminotransferase in the Phase 3 POISE Trial in Primary Biliary Cholangitis by Gish, Robert G., Wheeler, Darren, Li, Jing, Gasink, Christopher, Victor, David W.

Get full text

Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn’s Disease: The IM-UNITI Trial by Sandborn, William J., Rebuck, Rory, Wang, Yuhua, Zou, Bin, Adedokun, Omoniyi J., Gasink, Christopher, Sands, Bruce E., Hanauer, Stephen B., Targan, Stephan, Ghosh, Subrata, de Villiers, Willem J.S., Colombel, Jean-Frederic, Feagan, Brian G., Lynch, John P.

“…The IM-UNITI study and long-term extension (LTE) evaluated the long-term efficacy, safety, and immunogenicity of subcutaneous ustekinumab maintenance therapy…”
Get full text

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease by Feagan, Brian G, Sandborn, William J, Gasink, Christopher, Jacobstein, Douglas, Lang, Yinghua, Friedman, Joshua R, Blank, Marion A, Johanns, Jewel, Gao, Long-Long, Miao, Ye, Adedokun, Omoniyi J, Sands, Bruce E, Hanauer, Stephen B, Vermeire, Severine, Targan, Stephan, Ghosh, Subrata, de Villiers, Willem J, Colombel, Jean-Frédéric, Tulassay, Zsolt, Seidler, Ursula, Salzberg, Bruce A, Desreumaux, Pierre, Lee, Scott D, Loftus, Edward V, Dieleman, Levinus A, Katz, Seymour, Rutgeerts, Paul

“…In two trials in patients with moderately to severely active Crohn's disease, intravenous ustekinumab was effective in those who did not have a response to…”
Get full text

IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn’s Disease by Hanauer, Stephen B, Sandborn, William J, Feagan, Brian G, Gasink, Christopher, Jacobstein, Douglas, Zou, Bin, Johanns, Jewel, Adedokun, Omoniyi J, Sands, Bruce E, Rutgeerts, Paul, de Villiers, Willem J S, Colombel, Jean-Frédéric, Ghosh, Subrata

“…Abstract Background and Aims Following induction/maintenance treatment in the UNITI/IM-UNITI studies of ustekinumab for Crohn’s disease, patients entered a…”
Get full text

S178 Obeticholic Acid Normalizes Inflammatory Biomarkers in Patients With Primary Biliary Cholangitis by Foston, Tenita, Jones, David E., Bowlus, Christopher L., Thranian, Arash, Erickson, Mary, Li, Jing, Gasink, Christopher, Gish, Robert G.

Get full text

S124 Association of Elevated Liver Biochemistries and Clinical Outcomes Within Strata of Alkaline Phosphatase Levels in Patients With Primary Biliary Cholangitis by Victor, David W., MacEwan, Joanna P., Hernandez, Jennifer, Nair, Radhika, Kamal, Mustafa, Wheeler, Darren, Li, Jing, Bessonova, Leona, Gasink, Christopher, Kowdley, Kris V.

Get full text

S57 Impact of the HLA-DQA105 Allele on Ustekinumab Loss of Response, Anti-drug Antibodies, and Concentration in Patients With Inflammatory Bowel Disease by Colombel, Jean-Frederic, Martín-Arranz, María D, Brinkman, Brigitta, Gasink, Christopher, Guan, Meijian, Hart, Amy, Ahmad, Tariq

Get full text

S932 Active Tuberculosis and Opportunistic Infections: Pooled Safety Analysis of Ustekinumab Through up to 5 Years Across All Approved Indications by Loftus, Edward V., Long, Millie, Ott, Elyssa, Gasink, Christopher, Baker, Thomas, Goodwin, Bridget, Miao, Ye, Ghosh, Subrata

Get full text

S723 Improvements in Work Productivity Loss and Associated Cost Reductions with Ustekinumab and Adalimumab in Biologic-Naïve Patients with Moderately-to-Severely Active Crohn’s Disease: Results From the SEAVUE Study by Ding, Zhijie, Muser, Erik, Hoops, Timothy, Izanec, James L., Ma, Tony, Gao, Long-Long, Gasink, Christopher

Get full text

S842 Pharmacokinetics, Exposure-Response Relationships, and Immunogenicity in Crohn’s Disease Patients With Ustekinumab Secondary Loss of Response Following Ustekinumab IV Re-Induction: Week 16 Results From the POWER Study by Feagan, Brian G., Lee, Scott D., Janneke van der Woude, C., Marín-Jiménez, Ignacio, Wolf, Douglas C., Schnoy, Elisabeth, Salzberg, Bruce, Busse, Christopher, Nazar, Maciej, Langholff, Wayne, Gasink, Christopher, Baker, Thomas, Godwin, Bridget, Adedokun, Omoniyi, Schreiber, Stefan

Get full text

S1035 Analysis of Baseline Characteristics Associated With Clinical Response to Ustekinumab IV Re-Induction Strategy in Patients With Crohn’s Disease in the POWER Trial by Wolf, Douglas C., Lee, Scott D., Schreiber, Stefan, Janneke van der Woude, C., Marín-Jiménez, Ignacio, Schnoy, Elisabeth, Salzberg, Bruce, Busse, Christopher, Nazar, Maciej, Langholff, Wayne, Gasink, Christopher, Baker, Thomas, Godwin, Bridget, Feagan, Brian G.

“…Introduction: The 36-week (W) POWER trial evaluated the efficacy and safety of a single intravenous (IV) re-induction ustekinumab (UST) dose vs continued UST…”
Get full text

S1073 Clinical Outcomes and Biomarker Normalization Response at Week 16 in Patients With Inadequate Response or Intolerance to Prior Biologics in the POWER Trial by Lee, Scott D., Schreiber, Stefan, Janneke van der Woude, C., Marín-Jiménez, Ignacio, Wolf, Douglas C., Schnoy, Elisabeth, Salzberg, Bruce, Busse, Christopher, Nazar, Maciej, Langholff, Wayne, Gasink, Christopher, Baker, Thomas, Godwin, Bridget, Feagan, Brian G.

Get full text

S885 Safety of Ustekinumab in Older IBD Patients (≥60 Years): Pooled Safety Analysis Through 5 Years in CD and 2 Years in UC and All Approved Indications by Abreu, Maria T., Ott, Elyssa, Gasink, Christopher, Miao, Ye, Marano, Colleen, Lynch, John, Charabaty, Aline, Ghosh, Subrata

Get full text

S930 Safety of Ustekinumab Across Approved Adult Indications: Pooled Safety Analysis in Crohn’s Disease, Ulcerative Colitis, Psoriasis, and Psoriatic Arthritis Through up to 5 Years by Long, Millie D., Danese, Silvio, Ott, Elyssa, Gasink, Christopher, Miao, Ye, Baker, Thomas, Tikhonov, Ilia, Rahman, Proton, Strober, Bruce, Loftus, Edward V.

Get full text

Effector and memory CD8 + T cell fate coupled by T-bet and eomesodermin by Reiner, Steven L, Intlekofer, Andrew M, Takemoto, Naofumi, Wherry, E John, Longworth, Sarah A, Northrup, John T, Palanivel, Vikram R, Mullen, Alan C, Gasink, Christopher R, Kaech, Susan M, Miller, Joseph D, Gapin, Laurent, Ryan, Kenneth, Russ, Andreas P, Lindsten, Tullia, Orange, Jordan S, Goldrath, Ananda W, Ahmed, Rafi

“…Two seemingly unrelated hallmarks of memory CD8(+) T cells are cytokine-driven proliferative renewal after pathogen clearance and a latent effector program in…”
Get full text

S851 Health-Related Quality of Life With Ustekinumab vs Adalimumab for Induction and Maintenance Therapy in Biologic-Naïve Patients With Moderate-To-Severe Crohn’s Disease: PROMIS-29 in the SEAVUE Study by Lewis, James D., Allez, Matthieu, Irving, Peter M., Hoops, Timothy, Izanec, James L., Ma, Tony, Ding, Zhijie, Muser, Erik, Gasink, Christopher, Panaccione, Remo, Loftus, Edward V., Danese, Silvio, Sands, Bruce E.

Get full text

S770 Health-Related Quality of Life With Ustekinumab vs Adalimumab for Induction and Maintenance Therapy in Biologic-Naïve Patients With Moderate-To-Severe Crohn’s Disease: IBDQ in the SEAVUE Study by Loftus, Edward V., Danese, Silvio, Panaccione, Remo, Hoops, Timothy, Izanec, James L., Ma, Tony, Ding, Zhijie, Muser, Erik, Gasink, Christopher, Irving, Peter M., Allez, Matthieu, Sandborn, William J.

Get full text